Aegis Capital Maintians Synergy Pharma (SGYP) at 'Buy' Following Plecanatide Phase 3 Initiations; Strong Phase 2b Results May Carryover
Tweet Send to a Friend
Aegis Capita affirms Synergy Pharma (Nasdaq: SGYP) at Buy with a price target of $10 following news that the pharma ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
